Clinical Trials Browser

Phase 3 × Has announcements × Dexamethasone × Clear all

NCT03652064 2026-06-02

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3 Completed

395 enrolled 11 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Phase 3 Active not recruiting

488 enrolled 13 charts 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05083169 2026-05-08

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 1 FDA

Plasma cell

Multiple Myeloma

NCT03319667 2026-05-04

IMROZ

Phase 3 Active not recruiting

475 enrolled 1 FDA

Plasma cell

Multiple Myeloma

NCT04246047 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT03710603 2026-02-10

Perseus

Phase 3 Active not recruiting

709 enrolled 17 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT03275285 2026-02-09

IKEMA

Phase 3 Completed

302 enrolled 38 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT03180736 2025-12-19

EMN14

Phase 3 Completed

304 enrolled 19 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT03201965 2025-11-26

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Phase 3 Completed

416 enrolled 28 charts 2 FDA

Plasma cell

Amyloidosis

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Phase 3 Active not recruiting

245 enrolled 15 charts 1 FDA

LymphoidOther hematologic neoplasm

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT02252172 2025-10-20

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

737 enrolled 30 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT03158688 2025-05-09

CANDOR

Phase 3 Completed

466 enrolled 33 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT02541383 2025-04-13

Cassiopeia

Phase 3 Completed

1,085 enrolled 22 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT02990338 2025-01-17

ICARIA-MM

Phase 3 Completed

307 enrolled 32 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT02578680 2024-09-20

MK-3475-189

Phase 3 Completed

616 enrolled 19 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 1 FDA

Plasma cell

Multiple Myeloma, Recurrence

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 3 Completed

111 enrolled 23 charts 1 FDA

LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma